Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy

Brandon S. Imber, Michel Sadelain, Carl DeSelm, Connie Batlevi, Renier J. Brentjens, Parastoo B. Dahi, Sergio Giralt, Jae H. Park, Craig Sauter, Michael Scordo, Gunjan Shah, Miguel Angel Perales, M. Lia Palomba, Joachim Yahalom

Research output: Contribution to journalArticlepeer-review

26 Scopus citations

Abstract

Radiotherapy is potentially an important salvage strategy post-chimeric antigen receptor T cell therapy (CART), but limited data exist. We reviewed 14 patients treated with salvage radiation post-CART progression (SRT). Most received SRT for first post-CART relapse (71%) to sites previously PET-avid pre-CART (79%). Median overall survival (OS) post-SRT was 10 months. Post-SRT, six localized relapses achieved 100% response (3 = complete, 3 = partial), with improved freedom from subsequent relapse (P = 0·001) and OS (P = 0·004) compared to advanced stage relapses. Three were bridged to allogeneic transplantation; at analysis, all were alive/NED. SRT has diverse utility and can integrate with novel agents or transplantation to attempt durable remissions.

Original languageEnglish
Pages (from-to)45-51
Number of pages7
JournalBritish Journal of Haematology
Volume190
Issue number1
DOIs
StatePublished - Jul 1 2020

Keywords

  • CAR T cells
  • chimeric antigen receptor T cells
  • diffuse large B cell lymphoma
  • radiotherapy
  • relapsed/refractory
  • salvage therapy

Fingerprint

Dive into the research topics of 'Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy'. Together they form a unique fingerprint.

Cite this